Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may foretell MS's next move

NCT ID NCT07788573

Knowledge-focused Sponsor: Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study investigates whether a protein called FCRL5, found on certain immune cells, can serve as a marker for multiple sclerosis (MS) activity and treatment response. Researchers will track MS patients with blood tests every six months for two years, and compare their results with healthy volunteers and people with Sjögren's syndrome. The goal is to understand how FCRL5-expressing B cells contribute to MS and whether they can predict new brain lesions or how well a treatment works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A blood test every 6 months for MS patients; a single blood draw for healthy volunteers and Sjögren's syndrome volunteers
What this could lead to
If FCRL5 proves reliable, it could become a simple blood test to help predict MS progression and tailor treatments for individual patients.
What could go wrong
This is an observational study, so it won't directly test a treatment. The findings may not translate into a clinical tool without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with MS and healthy controls

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For MS patients: * Male or female * Between 18 and 80 years of age * Diagnosed with MS according to the most recent McDonald criteria (2025) * Patients who are about to start a new MS treatment or switch treatments For healthy volunteers: * Men or women * Ages 18 to 80 * Healthy volunteers with no neurological conditions or autoimmune diseases For participants with Sjögren's syndrome: * Men or women * Ages 18 to 80 Exclusion Criteria: * For MS patients: * No recent relapse (during the 3 months prior to study enrollment) * Patients treated with corticosteroids (during the 3 months prior to study enrollment) * Patients receiving another immunosuppressive therapy unrelated to MS * Inability to sign the informed consent form For healthy volunteers: Subjects not receiving immunosuppressive therapy For subjects with Sjögren's syndrome: Subjects not receiving immunosuppressive therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Université Catholique de Louvain

    Brussels, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.